מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
DARUNAVIR (DARUNAVIR ETHANOLATE); COBICISTAT
JANSSEN INC
J05AR14
DARUNAVIR AND COBICISTAT
800MG; 150MG
TABLET
DARUNAVIR (DARUNAVIR ETHANOLATE) 800MG; COBICISTAT 150MG
ORAL
30
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0255810001; AHFS:
APPROVED
2014-06-19
Non Ann PM PRCB SNDS 268359 02222023.docx EDMS-ERI-840430 V8.0_ _ _Page 1 of 65_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PREZCOBIX ® darunavir (as darunavir ethanolate)/cobicistat film-coated tablets (800 mg/150 mg) Human Immunodeficiency Virus (HIV) Protease Inhibitor Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 www.janssen.com/canada Date of Initial Authorization: June 18, 2014 Date of Revision: March 3, 2023 Submission Control Number: 268359 © 2023 Janssen Inc. All trademarks used under license. Non Ann PM PRCB SNDS 268359 02222023.docx EDMS-ERI-840430 V8.0_ _ _Page 2 of 65_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 08/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .............................................................................. 2 TABLE OF CONTENTS .................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................... 4 1 INDICATIONS ......................................................................................................... 4 1.1 Pediatrics .............................................................................................................. 4 1.2 Geriatrics .............................................................................................................. 4 2 CONTRAINDICATIONS ......................................................................................... 4 4 DOSAGE AND ADMINISTRATION ....................................................................... 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment .............................................. 5 4.4 Administration ...................................................................................................... 7 4.5 Missed קרא את המסמך השלם